anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to the technology for disintoxicating white spot syndrome viruses of prawn embryos, which mainly makes use of organic iodine to kill the white spot syndrome viruses of the prawn embryos and to cut off the vertical propagation of the viruses. The present invention has the specific technical operation procedures that collecting ova, detecting the density of the ova, kill viruses by medicine, flushing the ova, etc. Firstly, the quality, the collection time and the collection density of the ova are ensured; the organic iodine is used as a disintoxicating agent to kill the viruses; the medicine concentration of 5 to 10 ppm is kept; medicine processing time of 10 to 15 minutes is mastered. The technical method can be used for large scale prawn seedling production, and provides high health seedlings without the viruses. Through production and application, the disintoxicating rate of the white spot syndrome viruses of the prawn embryos is as high as 100%. The hatching rate of the ova is stable, and is above 85%. In addition, the present invention can ensure the normal proceeding of production.
During a one-month intervention period, the investigators will pilot test the educational strategies in three participating UPMC ICUs. Prior to receiving education, participants will be invited to complete a short online survey. Participants in the control group will be invited to complete a 30-minute online continuing education module, which will conclude with a survey. Participants in the interprofessional education group will be invited to attend a 90-minute, in-person, interprofessional education session that will occur in or near the participating ICU. A trained advance practice provider will provide participants in the just-in-time education group with 5-10 minutes of education in the ICU when the ICU team is rounding on a patient who is identified to be high risk for extubation failure. The just-in-time education may occur more than once per day, depending on the number of high-risk patients identified. All educational strategies will include content on the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV. Each educational intervention will include a survey designed to determine the feasibility, acceptability, and preliminary impact of the educational strategies. The investigators will also directly observe instances of interprofessional and just-in-time education and conduct in-person interviews to assess these factors in a qualitative manner. Lastly, during the intervention period and the 6 months before and after the intervention period, the investigators will collect data from the electronic health record and analyze changes in percent of high-risk patients who receive preventive post-extubation NIV, reintubation rate, duration of mechanical ventilation, ventilator-associated pneumonia, and in-hospital mortality.
FIELD: medicine. ^ SUBSTANCE: invention refers to dentistry, namely to an oral antiplaque composition, containing an orally acceptable carrier and an antibacterial effective amount of compound of formula (I). The tooth-paste or gel composition containing at least one moistening agent and at least one abrasive compound, and the oral antiplaque composition. Method of inhibiting bacterial growth in an animal's oral cavity by applying the antibacterial composition including the compound of formula (I) on the surface of the animal's oral cavity. ^ EFFECT: declared composition shows high antibacterial efficiency. ^ 25 cl, 1 ex
###  Children

In children 3 to 8 years old the mean half-life of diazepam has been reported to be 18 hours.

###  Newborns

In full term infants, elimination half-lives around 30 hours have been reported, with a longer average half-life of 54 hours reported in premature infants of 28 to 34 weeks gestational age and 8 to 81 days post-partum. In both premature and full term infants the active metabolite desmethyldiazepam shows evidence of continued accumulation compared to children. Longer half-lives in infants may be due to incomplete maturation of metabolic pathways.

###  Geriatric

Elimination half-life increases by approximately 1 hour for each year of age beginning with a half-life of 20 hours at 20 years of age. This appears to be due to an increase in volume of distribution with age and a decrease in clearance. Consequently, the elderly may have lower peak concentrations, and on multiple dosing higher trough concentrations. It will also take longer to reach steady-state. Conflicting information has been published on changes of plasma protein binding in the elderly. Reported changes in free drug may be due to significant decreases in plasma proteins due to causes other than simply aging.

###  Hepatic Insufficiency

In mild and moderate cirrhosis, average half-life is increased. The average increase has been variously reported from 2-fold to 5-fold, with individual half-lives over 500 hours reported. There is also an increase in volume of distribution, and average clearance decreases by almost half. Mean half-life is also prolonged with hepatic fibrosis to 90 hours (range 66 to 104 hours), with chronic active hepatitis to 60 hours (range 26 to 76 hours), and with acute viral hepatitis to 74 hours (range 49 to 129). In chronic active hepatitis, clearance is decreased by almost half.
The present invention relates to compounds of formula (I), in which B, D, E, G, X, Y, Z, R1, R2 and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them. (I)
Benzoxazoles and benzthiazoles of the general formula <FORM:0974365/C1/1> wherein A is an oxygen or a sulphur atom, R is a 5-membered heterocyclic ring containing an oxygen, sulphur or nitrogen atom as the sole heteroatom, each of R1 and R2 is a hydrogen atom or a C1-5 alkyl, C1-5 alkoxy, C1-5 alkylthio, aryloxy or arylthio radical; or, R1 and R2 together represent the 1, 4-butadienyl radical may be prepared by: (A) the reaction of an o-aminophenol or o-aminothiophenol with a heterocyclic carboxylic acid; when the substituents in the 5- and/or 6-positions are alkyl, alkoxy, aryloxy, alkylthio or arylthio substituents, the phenol derivatives are substituted with such groups in the 4 and/or 5 positions; (B) by the same reaction using the acid halide, lower alkyl ester, amide or nitrile in place of the heterocyclic free carboxylic acid; (C) by reaction of the o-amino-phenol or -thio-phenol with an aldehyde derivative of the heterocyclic ring compound.  Specific examples relate to the preparation of 2-(21-thienyl)-benzoxazole and 2-(21-furyl)-benzoxazole by method (A) above and 2-(21-pyrryl)-benzothiazole by method (C) above, 2(21-pyrryl)-benzothiazoline being formed as an intermediate and converted to the required compound by treatment with ferric chloride in ethanol.ALSO:Anthelmintic compositions comprise an orally ingestible diluent in which is uniformly distributed a compound of the general formula <FORM:0974365/A5-A6/1> wherein A is an oxygen or sulphur atom, each of R1 and R2 is a hydrogen atom or a C1-5 alkyl, C1-5-alkoxy, C1-5 alkylthio, aryloxy or arylthio group or R1 and R2 together represent a 1,4-butadienyl radical and R is a 5-membered heterocyclic ring containing an oxygen, sulphur or nitrogen atom as the sole hetero atom.  The compositions may be in conventional veterinary forms, e.g. a bolus or drench or they may be in the form of an animal feedstuff, salt-block, premixes or feed supplements, e.g. a protein and vitamin supplement for use as a "top dressing" for feeds of the larger domesticated animals.  The invention also comprises the process of combating helminthiasis in commercially reared animals by administering the compositions or active compounds of the invention.
An embodiment of the present invention is directed to a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines comprising: a protein carrier comprising an inserted nucleic acid consensus sequence; at least one polysaccharide such as a capsular Gram-positive polysaccharide linked to the consensus sequence; and, optionally, an adjuvant or pharmaceutically acceptable carrier. In a further aspect, the instant invention is directed to methods of producing Gram positive and other bioconjugate vaccines. In another aspect, an N-glycosylated protein is provided that comprises one or more polysaccharides such as Gram-positive polysaccharides. The present invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine. Further, the invention is directed to methods of inducing an immune response in a mammal comprising administering said bioconjugate vaccines.
Disturbances of mineral and bone diseaeses are frequently observed in CKD patients. Renal osteodystrophy is the term to describe the bone abnormalities. Epidemiological data showed adynamic bone disease (ABD) is the most frequent bone disorder in CKD stage 5D diseases. Low PTH, diabetes mellitus, malnutrition, metabolic acidosis, hypogonadism and low 1,25(OH)2D vitamin D deficiency are known risk factors for ABD. Mounting experimental data point towards a role of protein-bound uremic retention molecules (p-cresyl sulfate and indoxyl sulfate) in the pathogenesis and progression of ABD. ABD is not only recognized as a risk factor for fractures but also for arterial calcification.

The aim of the present study is (1) to investigate the role of indoxyl sulfate and p-cresyl sulfate in the pathogenesis and progression of ABD and arterial calcification in CKD stage5 and (2) to investigate the influence of renal transplantation on bone and arterial metabolism.
Increases in serum transaminases have been reported with use of atorvastatin calcium [see Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. Persistent increases to more than three times the ULN in serum transaminases have occurred in approximately 0.7% of patients receiving atorvastatin calcium in clinical trials. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. 

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Use in Specific Populations (8.7)].

Consider liver enzyme testing before atorvastatin calcium tablets initiation and when clinically indicated thereafter. Atorvastatin calcium is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue atorvastatin calcium tablets.
Sepsis induces immune alterations, which last for months after the resolution of illness. The effect of this immunological reprogramming on the risk of developing cancer is unclear. Here we use a national claims database to show that sepsis survivors had a lower cumulative incidence of cancers than matched nonsevere infection survivors. We identify a chemokine network released from sepsis-trained resident macrophages that triggers tissue residency of T cells via CCR2 and CXCR6 stimulations as the immune mechanism responsible for this decreased risk of de novo tumor development after sepsis cure. While nonseptic inflammation does not provoke this network, laminarin injection could therapeutically reproduce the protective sepsis effect. This chemokine network and CXCR6 tissue-resident T cell accumulation were detected in humans with sepsis and were associated with prolonged survival in humans with cancer. These findings identify a therapeutically relevant antitumor consequence of sepsis-induced trained immunity.
102 subjects from the pool of patients hospitalized in our pulmonary clinics will be randomized in 1:1 ratio to 2 arms in double blinded manner. Subjects in both arms will inhale first vial of study medication - furosemide 40 mg or placebo (saline). Dyspnea severity and vital functions will be measured, adverse reactions will be monitored. After an hour the subjects will inhale the second vial of study medication followed by the same procedure as earlier. Neither subjects, nor investigators will know which vial contains furosemide and which contains placebo. At last all subjects will receive levodropropizine open label and the dyspnea severity, vital signs and adverse reaction will be monitored for another hour. The measured values will be statistically evaluated a results published.
All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. After the ultrasound assessment, the control group will wait in another room for approximately 30 minutes.
Group 3 (select solid tumor patients): Patients receive oral isotretinoin twice daily on days 1-14. Patients also receive SAHA once daily on days 1-28 OR once on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.The MTD of SAHA is determined as in group 1. An additional 6 patients may be treated at the MTD.
Elderly patients (aged 65 years or older) may have increased sensitivity to Nalbuphine Hydrochloride Injection. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of Nalbuphine Hydrochloride Injection slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system ‎and respiratory depression [see WARNINGS].

Nalbuphine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
A method of diagnosing and for therapeutic treatment of tumors and of infectious diseases by administering effective amounts of cytostatic compositions of alkaloid compounds, their derivatives, salts of the alkaloid compounds, salts of said derivatives or mixtures thereof. The alkaloid component causes stimulation of the cellular defense mechanism, exhibits a great affinity for tumor cells with rapid accumulation in the tumor cells, interferes with cellular activity of tumor cells and cells attacked by virus and other antigens, and destroys malignant tumors and other antigen structures such as viruses, bacteria, fungal organisms. The alkaloid component can be unlabelled or labelled with radioactive isotopes. The compositions may contain materials which are fluorescent under U.V. light or compounds which absorb X-rays. In addition, the compositions can be used as an analgesic in the treatment of polyarthritis and as post-operative anti-inflammation reagent.
BACKGROUND: With the development of artificial intelligence, the application of machine learning to develop predictive models for sepsis-associated acute kidney injury has made potential breakthroughs in early identification, grading, diagnosis, and prognosis determination.
METHODS: Here, we conducted a systematic search of the PubMed, Cochrane Library, Embase (Ovid), Web of Science, and Scopus databases on April 28, 2023, and screened relevant literature. Then, we comprehensively extracted relevant data related to machine learning algorithms, predictors, and predicted objectives. We subsequently performed a critical evaluation of research quality, data aggregation, and analyses.
RESULTS: We screened 25 studies on predictive models for sepsis-associated acute kidney injury from a total of originally identified 2898 studies. The most commonly used machine learning algorithm is traditional logistic regression, followed by eXtreme gradient boosting. We categorized these predictive models into early identification models (60%), prognostic prediction models (32%), and subtype identification models (8%) according to their predictive purpose. The five most commonly used predictors were serum creatinine levels, lactate levels, age, blood urea nitrogen concentration, and diabetes mellitus. In addition, a single data source, insufficient assessment of clinical utility, lack of model bias assessment, and hyperparameter adjustment may be the main reasons for the low quality of the current research.
CONCLUSIONS: However, studies on the nondeath prognostic outcomes, the long-term clinical outcomes, and the subtype identification models are insufficient. Additionally, the poor quality of the research and the insufficient practicality of the model are problems that need to be addressed urgently.
The invention relates to a preparation method of pearl powder capsule with high calcium and high zinc. The preparation method includes the following procedures: the pearls are selected; after washed, the selected pearls are dried to sterilize; the dried pearls are crushed by the machine and are made to pass through the screen, and fine powder whose particle size is less than 100 orders is prepared; and then the fine powder is crushed by airflow to be 50 to 100 nanometers; then 65 to 98 percent weight parts of nanometer pearl micropowder and 2 to 35 percent weight parts of zinc gluconate or zinc lactate or yeast biozinc are well mixed, and finished product of powder is prepared; the finished product of powder is processed into the pearl powder capsules with high calcium and high zinc; and finally, the pearl powder capsules with high calcium and high zinc are filled into bottles and then the bottles are packaged. The invention can supplement calcium and zinc. Natural pearls contain more than 20 kinds of amino acids, trace elements needed by the human body and plenty of biological active calcium carbonate, so the natural pearls have functions of clearing heart and tranquilization, diminishing inflammation and reducing pathogenic fire, protecting eyes and improving eyesight, holding moisture and moistening the skin, and resisting wrinkle and lightening skin, etc. Zinc can promote physical development and intelligence and can enhance the immune function. The yeast biozinc is the organic combination of zinc and protein inside the yeast; the biological absorption is high; and the yeast biozinc has no toxic side effects on the human body or stimulation on the  intestine and stomach.
Participants will ingest a placebo supplement containing no beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
PURPOSE:A fomentation useful for the skin and various diseases, having no side effects, easily handleable, obtained by blending fermented wild Indian rice leaf powder with dry-preventing honey. CONSTITUTION:The whole leaves of wild Indian rice are crushed, steamed, sterilized, celluose is decomposed, an enzyme mold is added to the treated wild Indian rice, which is put in a chamber and fermented. It is dried by the sun, put in a dryer, and powdered by a mill. 1pt.wt. Fermented wild Indial rice leaf powder is well blended with 9pts.wt. natural honey, to give a fomentation. When it is used, it is directly applied to the affected part, and it may be protected with cotton gauze, etc. Or preferably it is preapplied to an inner curved surface of a proper permeable split-cavity mold, the mold is brought into contact with an affected part corresponding to the curved surface, and it is fixed by a bandage. EFFECT:The titled fomentation is obtainable by a simple process, preservable, and it is processed into a commodity without losing its effects.
The GhEB1C gene of the EB1 protein family functions as microtubule end-binding protein and may be involved in the regulation of microtubule-related pathways to enhance resistance to Verticillium wilt. The expression of GhEB1C is induced by SA, also contributing to Verticillium wilt resistance. Cotton, as a crucial cash and oil crop, faces a significant threat from Verticillium wilt, a soil-borne disease induced by Verticillium dahliae, severely impacting cotton growth and development. Investigating genes associated with resistance to Verticillium wilt is paramount. We identified and performed a phylogenetic analysis on members of the EB1 family associated with Verticillium wilt in this work. GhEB1C was discovered by transcriptome screening and was studied for its function in cotton defense against V. dahliae. The RT-qPCR analysis revealed significant expression of the GhEB1C gene in cotton leaves. Subsequent localization analysis using transient expression demonstrated cytoplasmic localization of GhEB1C. VIGS experiments indicated that silencing of the GhEB1C gene significantly increased susceptibility of cotton to V. dahliae. Comparative RNA-seq analysis showed that GhEB1C silenced plants exhibited altered microtubule-associated protein pathways and flavonogen-associated pathways, suggesting a role for GhEB1C in defense mechanisms. Overexpression of tobacco resulted in enhanced resistance to V. dahliae as compared to wild-type plants. Furthermore, our investigation into the relationship between the GhEB1C gene and plant disease resistance hormones salicylic axid (SA) and jasmonic acid (JA) revealed the involvement of GhEB1C in the regulation of the SA pathway. In conclusion, our findings demonstrate that GhEB1C plays a crucial role in conferring immunity to cotton against Verticillium wilt, providing valuable insights for further research on plant adaptability to pathogen invasion.